Equity research analysts covering Ocugen, Inc. (NASDAQ: OCGN) maintain varying twelve-month forward-looking price targets, with consensus projections reflecting significant potential percentage upside from its prevailing micro-cap trading levels. Wall Street brokerages tracking the biotechnology firm report average consensus targets hovering around $9.50 to $11.00 per share, supported by bullish evaluations of its clinical-stage gene therapy pipeline targeting blindness diseases and retinal disorders. However, individual analyst targets vary widely based on clinical trial success probabilities, regulatory milestones, and future capital requirements.